Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour

References

• Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655–664.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Jco. 2008;26:5352–5359.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–274.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58.
   PubMed Web of Science ®Google Scholar
• Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012;29:1765–1772.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. Jco. 2005;23:5795–5804.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134.
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338.
   PubMed Web of Science ®Google Scholar
• Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751–1757.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–632.
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Jco. 2007;25:1753–1759.
   PubMed Web of Science ®Google Scholar
• Program CTE. Common terminology criteria for adverse events version 3.0 (CTCAE). Bethesda: National Cancer Institute; 2003.
   Google Scholar
• Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015;121:1405–1413.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Song W, He YL, et al. Application of sunitinib in the treatment of advanced gastrointestinal stromal tumor. Chin J Dig Surg. 2013;12:280–284.
   Google Scholar
• Liu XF, Qin SK, Wang L, et al. Clinical observation of sunitinib as second-1ine treatment for Chinese pafients with recurrent or metastatic gastrointestinal stromal tumor. Chinese Clinical Oncology. 2013;18:636–639.
   Google Scholar
• Li J, Gao J, Hong J, et al. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Future Oncol. 2012;8:617–624.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang WZ, Guan GX, et al. Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:221–225.
   PubMedGoogle Scholar
• Chen YY, Yeh CN, Cheng CT, et al. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol. 2011;17:2113–2119.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 2016;16:22.
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma, Version 2.2017. In. 2017.
   Google Scholar
• Hsu CC, Wu CE, Chen JS, et al. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients. Anticancer Res. 2014;34:5029–5036.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Nannini M, Fumagalli E, et al. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2016;7:69412–69419.
   PubMedGoogle Scholar
• Hsu JT, Le PH, Kuo CF, et al. Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: a nationwide population-based cohort study. Oncotarget. 2017;8:71128–71137.
   PubMedGoogle Scholar
• Dong Z, Gao J, Gong J, et al. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes. Future Oncol. 2017;13:2035–2043.
   PubMed Web of Science ®Google Scholar